Terminated PHASE3 INTERVENTIONAL 2-arm NCT02240108

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease

Sponsor: Bausch Health Americas, Inc.

Conditions Crohn's Disease

Interventions Placebo Rifaximin EIR

Updated 13 times since 2017 Last updated: Sep 6, 2019 Started: Oct 28, 2014 Primary completion: Oct 6, 2017 Completion: Oct 6, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.

Other terminated trials from Bausch Health Americas, Inc.

More terminations from Bausch Health Americas, Inc.

Other Crohn's Disease trials with similar outcome

Browse all Crohn's Disease trials

Listed as NCT02240108, this PHASE3 trial focuses on Crohn's Disease and remains terminated or withdrawn. Sponsored by Bausch Health Americas, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 8 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Oct 2019 — Nov 2020 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Jun 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2017 — May 2018 [monthly]

Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch Health Americas, Inc.
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC

Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, United States , Atlanta, United States , Beavercreek, United States , Boca Raton, United States , Bridgeton, United States , Brockton, United States , Caro, United States , Chesapeake, United States , Chicago, United States , Cincinnati, United States and 60 more locations